The US drugs regulator has approved the sale of a new nasal spray to treat depression. Manufacturer Janssen says Esketamine can ... and can cost up to $885 (£673) per treatment.

Johnson & Johnson has priced its new Spravato nasal spray ... cost-effectiveness body. The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine ...

An esketamine-based nasal spray antidepressant for adults is under review in the US following a filing from Johnson & Johnson's pharma unit. Janssen has submitted a filing for esketamine to the US ...

"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

Results, published in CNS Spectrums, showed a significant improvement in symptoms for those taking a new OAD with esketamine ...